email   Email Us: info@lupinepublishers.com phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

ISSN: 2637-6679

Research and Reviews on Healthcare: Open Access Journal

Review Article(ISSN: 2637-6679)

Overview of COVID19 In Hypertension Patients

Volume 5 - Issue 4

Sarah Alqurmalah*

  • Author Information Open or Close
    • MBBS College of Medicine, Majmaah University, Kingdom of Saudi Arabia

    *Corresponding author: Sarah Ibrahim Alqurmalah, MBBS College of Medicine, Majmaah University, Kingdom of Saudi Arabia

Received: September 14, 2020;   Published: September 24, 2020

DOI: 10.32474/RRHOAJ.2020.05.000220

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Introduction: The coronavirus disease 2019 (COVID-19) is worldwide outbreak. Globally there are 21,159,730 reported confirmed cases and there is almost no country in the world that is not affected by COVID-19 (3). It is caused by severe acute respiratory syndrome coronavirus 2 respiratory syndrome coronavirus 2 (SARS-CoV-2) enter the cells through angiotensin converting enzyme 2 (ACE2) receptor that act as key regulator of blood pressure.

Objective: To summarize the most updated data on COVID-19 and hypertension.

Methodology: A PubMed and UpToDate search was completed in Clinical Queries using the key terms ‘COVID-19 in hypertension patients ‘and ‘COVID-19 ‘. The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, and reviews.

Result: 1099 patients with confirmed COVID-19, of which the single highest risk factor of infection was hypertension reported in 15% of patients. Meta-analysis of six studies (1527) patients, hypertension was present in 17.1% of patients with the infection. The median age of SARS-CoV-2–positive patients who died was 78.5 years. significantly higher usage of ARBs in hypertensive patients with moderate COVID-19 disease than those with a severe and critical course of disease. There is no advantage to any group of medications within RAAS inhibitors. There are no data regarding the association between RAAS inhibitors and the outcome.

Conclusion: There is a relation between COVID-19 and HTN and need more data to be clarify weather HTN is isolated risk factor or as a reflection of ACEI or ARB. Age is associated with COVID19.

Abbreviations: COVID-19; Hypertension; ACE; ARB

Abstract| Introduction| Hypertension| The association of HTN and COVID-19| The association of age and COVID-19| ACE2 and ARB| References|

Close

Online Submission System

Drag and drop files here

or

Browse Files
( For multiple files submission, zip them in a single file to submit. For file zipping software Download )